M&A Deal Summary

Rocket Pharma Acquires Renovacor

On September 20, 2022, Rocket Pharma acquired life science company Renovacor

Acquisition Highlights
  • This is Rocket Pharma’s 1st transaction in the Life Science sector.
  • This is Rocket Pharma’s 1st transaction in the United States.
  • This is Rocket Pharma’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2022-09-20
Target Renovacor
Sector Life Science
Buyer(s) Rocket Pharma
Deal Type Add-on Acquisition
Advisor(s) Wells Fargo Securities (Financial)
Troutman Pepper Hamilton Sanders (Legal)

Target

Renovacor

Greenwich, Connecticut, United States
Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Renovacor is based in Greenwich, Connecticut.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Rocket Pharma

Cranbury, New Jersey, United States
Category Company
Founded 1999
Sector Life Science
Employees268
Revenue 260M USD (2023)
DESCRIPTION

Rocket Pharma is a clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. Rocket Pharma's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket Pharma was founded in 1999 and is based in Cranbury, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Connecticut) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Mergr

Product

Company

Legal